Skip to main content
SpringerLink
Log in

Design Parameters for Drug-Coated Balloons II

  • Chapter
  • First Online:
Drug-Coated Balloons

  • 534 Accesses

Abstract

The drug-coated balloon (DCB) is an emerging device since the focus on the bioabsorbable stent has shifted due to its mixed results. Currently paclitaxel and sirolimus are two choices in DCBs and both drugs have their own advantages. Use of sirolimus on DCBs is not yet well known but may replace use of of paclitaxel in the coming years when key design criteria are compared. From the scientific perspective, researchers developing DCB in the laboratory need to consider certain criteria. DCB development needs to fulfill multiple criteria with regard to the drug, device, drug carrier, physicochemical properties of the drug and drug carrier, particle size and coating methodology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–S67.

    Article  Google Scholar 

  2. European Stroke Organisation, Tendera M, Aboyans V, ESC Committee for Practice Guidelines, et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851–906.

    Article  Google Scholar 

  3. Chalmers N, Walker PT, Belli AM, et al. Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study. Cardiovasc Intervent Radiol. 2013;36(2):353–61.

    Article  Google Scholar 

  4. Loh JP, Barbash IM, Waksman R. The current status of drug-coated balloons in percutaneous coronary and peripheral interventions. EuroIntervention. 2013;9(8):979–88.

    Article  Google Scholar 

  5. Zeller T, Schmitmeier S, Tepe G, et al. Drug-coated balloons in the lower limb. J Cardiovasc Surg. 2011;52(2):235–43.

    CAS  Google Scholar 

  6. Scheller B. The Invatec IN-PACT Falcon paclitaxel DEB: device description and clinical studies. In: Transcatheter Cardiovascular Therapeutics, Washington, DC, 21–25 Sep 2010.

    Google Scholar 

  7. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003;3:193–203.

    Article  CAS  Google Scholar 

  8. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88:2619–28.

    Article  CAS  Google Scholar 

  9. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277–83.

    Article  CAS  Google Scholar 

  10. Marks AR. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med. 2003;349:1307–9.

    Article  CAS  Google Scholar 

  11. Hwang C-W, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 2001;104:600–5.

    Article  CAS  Google Scholar 

  12. Schwartz SM. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest. 1997;100:S87–9.

    CAS  PubMed  Google Scholar 

  13. Levin AD, Vukmirovic N, Hwang C-W, et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A. 2004;101:9463–7.

    Article  CAS  Google Scholar 

  14. Gervasoni JE Jr, Hindenburg AA, Vezeridis MP, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004;24:2617–26.

    CAS  PubMed  Google Scholar 

  15. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res. 2000;86:879–84.

    Article  CAS  Google Scholar 

  16. Yang C, Burt HM. Drug-eluting stents: factors governing local pharmacokinetics. Adv Drug Deliv Rev. 2006;58:402–11.

    Article  CAS  Google Scholar 

  17. Bozsak F, Gonzalez-Rodriguez D, Sternberger Z, Belitz P, Bewley T, Chomaz J-M. Optimization of drug delivery by drug-eluting stents. PLoS One. 2015;10(6):e0130182.

    Article  Google Scholar 

  18. Revolvy. Butyryl trihexyl citrate topics. https://www.revolvy.com/main/index.php?s=Butyryl%20trihexyl%20citrate&stype=topics&cmd=list. Accessed 7 Dec 2017.

  19. Lemos Neto PA, Farooq V, Takimura CK, Gutierrez PS, Virmani R, Kolodgie F, et al. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013;9(1):146–56. https://doi.org/10.4244/EIJV9I1A21.

    Article  Google Scholar 

  20. Takimura CK, Galon MZ, Sojitra P, Doshi M, et al. Excipient:drug dose determination for neointimal hyperplasia as assessed by optical coherence tomography and histopathology in porcine coronary arteries after sirolimus-eluting balloon deployment. Rev Bras Cardiol Invasiva. 2012;20(2):133–9.

    Google Scholar 

  21. Cortese B, di Palma G, Latini RA, Elwany M, Orrego PS, Seregni RG. Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The Fatebenefratelli Sirolimus Coated-Balloon (FASICO) registry. Cardiovasc Revasc Med. 2017;18(7):487–91.

    Article  Google Scholar 

  22. Granada JF, et al. In vivo delivery and long-term tissue retention of nano-encapsulated sirolimus using a novel porous balloon angioplasty system. EuroIntervention. 2016;12:740–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Concept Medical Research Private Limited, Surat, India

    Manish Doshi & Prakash Sojitra

  2. William Beaumont Hospital, Royal Oak, MI, USA

    Dinesh Shah

Authors
  1. Manish Doshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dinesh Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prakash Sojitra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prakash Sojitra .

Editor information

Editors and Affiliations

  1. Cardiac Department, San Carlo Clinic, Milano, Italy

    Bernardo Cortese

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Doshi, M., Shah, D., Sojitra, P. (2019). Design Parameters for Drug-Coated Balloons II. In: Cortese, B. (eds) Drug-Coated Balloons . Springer, Cham. https://doi.org/10.1007/978-3-319-92600-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92600-1_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92599-8

  • Online ISBN: 978-3-319-92600-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation